What is the appropriate treatment for viral uveitis?

Treatment of Viral Uveitis

For viral anterior uveitis, initiate combination therapy with oral antivirals (acyclovir 400 mg five times daily, valacyclovir 500 mg 2-3 times daily, or famciclovir 250 mg twice daily) plus topical corticosteroids, with the specific antiviral agent selected based on the causative virus identified. 1

Pathogen-Specific Treatment Approach

Herpes Simplex Virus (HSV) Uveitis

• Topical antivirals: Ganciclovir 0.15% gel 3-5 times daily OR trifluridine 1% solution 5-8 times daily 1
• Oral antivirals: Acyclovir 200-400 mg five times daily, valacyclovir 500 mg 2-3 times daily, or famciclovir 250 mg twice daily 1
• Critical caveat: Topical corticosteroids potentiate HSV epithelial infections and should be avoided in isolated HSV conjunctivitis, but can be used with concurrent oral antiviral therapy for stromal keratitis 2
• Topical ganciclovir is less toxic to the ocular surface than trifluridine, which inevitably causes epithelial toxicity after 2 weeks 1

Varicella-Zoster Virus (VZV) Uveitis

• Oral antivirals: Acyclovir 800 mg five times daily for 7 days, valacyclovir 1000 mg every 8 hours for 7 days, or famciclovir 500 mg three times daily for 7 days 2, 1
• Topical antivirals alone are not helpful for VZV conjunctivitis but may be used as additive treatment in unresponsive patients 2, 1
• Chronic disease may require prolonged treatment with dose adjustment based on clinical response 2

Cytomegalovirus (CMV) Retinitis/Uveitis

For CMV retinitis in HIV-infected patients, oral valganciclovir is the preferred first-line treatment for peripheral lesions not immediately sight-threatening 3. For immediately sight-threatening lesions (adjacent to optic nerve or fovea), the ganciclovir intraocular implant plus oral valganciclovir is superior to systemic therapy alone 3.

Treatment options include:

• Oral valganciclovir (preferred for ease of administration and lack of catheter complications) 3
• Intravenous ganciclovir followed by oral valganciclovir 3
• Intravenous foscarnet 3
• Intravenous cidofovir 3
• Ganciclovir intraocular implant plus oral valganciclovir 3

Monitoring requirements:

• Dilated indirect ophthalmoscopy at diagnosis, after induction therapy completion, 1 month after initiation, then monthly while on treatment 4, 3
• Monthly fundus photographs using standardized technique provide optimal method for detecting early relapse 4, 3
• For patients with immune recovery, ophthalmologic follow-up frequency can decrease to every 3 months 4

Laboratory monitoring:

• For ganciclovir/foscarnet: Complete blood counts, serum electrolytes, and renal function twice weekly during induction, then weekly 4, 3
• For cidofovir: Blood urea nitrogen, creatinine, and urinalysis before each infusion; contraindicated if renal dysfunction or proteinuria detected 4

Adjunctive Therapy

Corticosteroids

• Topical corticosteroids (prednisolone acetate 1% or dexamethasone) are first-line for anterior uveitis when combined with antivirals 5
• Use minimum effective dose and taper slowly 1
• Corticosteroids with poor ocular penetration (fluorometholone, loteprednol) may reduce risk of elevated IOP and cataract 1
• Periocular or systemic corticosteroids may be needed for immune recovery uveitis (IRU), with estimated 50% response rates 4

Cycloplegics and IOP Management

• Cycloplegics should be added to prevent posterior synechiae 6
• Intraocular pressure-lowering medication as needed 6

Prophylactic Therapy

A 3-12 month course of prophylactic antiviral treatment against recurrences is worth considering 6. Lower doses of oral antivirals are appropriate for long-term prophylaxis against recurrent HSV keratitis 1.

For CMV anterior uveitis with recurrent disease, biweekly valganciclovir 450 mg may be considered as a reduced prophylactic dose to minimize side effects and financial burden 7.

Treatment Failure Management

For CMV retinitis relapse without immune recovery:

• First relapse: Reinduction with same drug followed by maintenance therapy controls retinitis, though for progressively shorter periods 4
• Ganciclovir implant placement is recommended for patients relapsing on systemic treatment, typically controlling retinitis for 6-8 months 4
• Combination ganciclovir plus foscarnet is superior to either agent alone but has greater toxicity 4
• Consider changing agents if drug resistance suspected or side effects interfere with optimal treatment 4

Special Considerations

Immune Recovery Uveitis (IRU)

IRU occurs as an immunologic reaction to CMV with inflammation in anterior chamber or vitreous, typically 4-12 weeks after ART initiation in patients with substantial CD4+ count rise 4. Treatment requires periocular corticosteroids or short courses of systemic corticosteroids; oral valganciclovir may be beneficial 4.

Severe Vitreous Opacity

For VZV-associated uveitis with severe vitreous opacity where antiviral therapy alone is insufficient, early vitrectomy is an effective therapeutic approach 8. This represents an important consideration when medical management fails to adequately clear inflammation.

Neonatal HSV

Neonates with HSV require prompt consultation with pediatrician or primary care physician, as systemic HSV infection is life-threatening 1.